Eden Sebbag, Kim Lauper, Juan Molina-Collada, Daniel Aletaha, Johan Askling, Karolina Gente, Heidi Bertheussen, Samuel Bitoun, Ertugrul Cagri Bolek, Gerd R Burmester, Helena M Canhão, Katerina Chatzidionysiou, Jeffrey R Curtis, Francois-Xavier Danlos, Vera Guimarães, Merete Lund Hetland, Florenzo Iannone, Marie Kostine, Tue Wenzel Kragstrup, Tore K Kvien, Anne Constanze Regierer, Hendrik Schulze-Koops, Lucía Silva-Fernández, Zoltan Szekanecz, Maya H Buch, Axel Finckh, Jacques-Eric Gottenberg
{"title":"2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.","authors":"Eden Sebbag, Kim Lauper, Juan Molina-Collada, Daniel Aletaha, Johan Askling, Karolina Gente, Heidi Bertheussen, Samuel Bitoun, Ertugrul Cagri Bolek, Gerd R Burmester, Helena M Canhão, Katerina Chatzidionysiou, Jeffrey R Curtis, Francois-Xavier Danlos, Vera Guimarães, Merete Lund Hetland, Florenzo Iannone, Marie Kostine, Tue Wenzel Kragstrup, Tore K Kvien, Anne Constanze Regierer, Hendrik Schulze-Koops, Lucía Silva-Fernández, Zoltan Szekanecz, Maya H Buch, Axel Finckh, Jacques-Eric Gottenberg","doi":"10.1136/ard-2024-225982","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Potential associations between targeted therapies and a new cancer in patients with inflammatory arthritis (IA) and a previous malignancy are a frequent concern in daily rheumatology practice.</p><p><strong>Objectives: </strong>To develop points to consider (PTC) to assist rheumatologists when initiating a targeted therapy in the context of a previous malignancy.</p><p><strong>Methods: </strong>Following EULAR standardised operating procedures, a task force met to define the research questions for a systematic literature review and to formulate the overarching principles (OPs) and the PTC.</p><p><strong>Results: </strong>The group formulated five OPs; seven PTC were formulated concerning the initiation of targeted therapies in patients with active IA and a previous malignancy in remission and one PTC concerning patients with active IA who were not in cancer remission. Major themes included (a) the need to assess the individualised risk of cancer recurrence based on the characteristics of the patient, cancer and the underlying disease; (b) the importance of engaging with specialists caring for cancer and defining treatment based on a shared decision between the patient and the rheumatologist; (c) the value of initiating without delay an appropriate targeted therapy for the treatment of the IA in patients in remission of their cancer; (d) the proposal to use Janus kinase inhibitors and abatacept with caution and in the absence of therapeutic alternatives, based on the absence of any data concerning their use in the context of previous malignancy.</p><p><strong>Conclusion: </strong>The 2024 EULAR points to consider provide guidance on the management of targeted therapies in patients with IA and a previous malignancy.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the Rheumatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ard-2024-225982","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Potential associations between targeted therapies and a new cancer in patients with inflammatory arthritis (IA) and a previous malignancy are a frequent concern in daily rheumatology practice.
Objectives: To develop points to consider (PTC) to assist rheumatologists when initiating a targeted therapy in the context of a previous malignancy.
Methods: Following EULAR standardised operating procedures, a task force met to define the research questions for a systematic literature review and to formulate the overarching principles (OPs) and the PTC.
Results: The group formulated five OPs; seven PTC were formulated concerning the initiation of targeted therapies in patients with active IA and a previous malignancy in remission and one PTC concerning patients with active IA who were not in cancer remission. Major themes included (a) the need to assess the individualised risk of cancer recurrence based on the characteristics of the patient, cancer and the underlying disease; (b) the importance of engaging with specialists caring for cancer and defining treatment based on a shared decision between the patient and the rheumatologist; (c) the value of initiating without delay an appropriate targeted therapy for the treatment of the IA in patients in remission of their cancer; (d) the proposal to use Janus kinase inhibitors and abatacept with caution and in the absence of therapeutic alternatives, based on the absence of any data concerning their use in the context of previous malignancy.
Conclusion: The 2024 EULAR points to consider provide guidance on the management of targeted therapies in patients with IA and a previous malignancy.
期刊介绍：
Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
